NRBO logo

NeuroBo Pharmaceuticals, Inc. Common Stock


NRBO: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.


Show NRBO Financials

Consumer Interest
SEC Filings

Recent trades of NRBO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by NRBO's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Composition containing mixed extract of mulberry and Mar. 16, 2021
  • Patent Title: Composition containing Dec. 15, 2020
  • Patent Title: Methods of reducing risk of cardiovascular disease Jul. 14, 2020
  • Patent Title: Composition containing mixed extract of mulberry and Mar. 17, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of NRBO in WallStreetBets Daily Discussion


Recent insights relating to NRBO

CNBC Recommendations

Recent picks made for NRBO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NRBO

Corporate Flights

Flights by private jets registered to NRBO